Amgen (AMGN) weekly option implied volatility increases into EPS and outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil prices, Treasury yields remain elevated
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
Amgen (AMGN) PT Raised to $195 at Barclays
July 27, 2018 6:56 AM EDTBarclays raised its price target on Amgen (NASDAQ: AMGN) to $195.00 (from $180.00) while maintaining a Equalweight rating following the company's 2Q earnings report.
Amgens portfolio looks poised to deliver flat growth in 2018e, which, in Barclays view, will likely keep... More
Amgen (AMGN) PT Raised to $210 at Piper Jaffray Following 2Q
July 27, 2018 6:45 AM EDTPiper Jaffray raised its price target on Amgen (NASDAQ: AMGN) to $210.00 (from $190.00) while maintaining a Overweight rating following the company's 2Q earnings report. AMGN posted Q218 non-GAAP EPS of $3.83, well ahead of consensus $3.55. Upside was operationally driven as revenue beat handily (total revenue was... More
